Net Deals Web Search

Search results

1. Results From The WOW.Com Content Network

2. Amgen's Denosumab Approved for Cancer Patients - AOL

   www.aol.com/2010/11/19/amgens-denosumab-approved...

   The Food and Drug Administration has approved Amgen's (AMGN) osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication ...

3. Denosumab - Wikipedia

   en.wikipedia.org/wiki/Denosumab

   Denosumab, sold under the brand names Prolia and Xgeva among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [8] [9] Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle ...

4. Amgen - Wikipedia

   en.wikipedia.org/wiki/Amgen

   Contents. Amgen. Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total. [5] The name "AMGen" is a portmanteau of the ...

5. List of largest selling pharmaceutical products - Wikipedia

   en.wikipedia.org/wiki/List_of_largest_selling...

   Some most selling products needed to registered by the REMS program, there are different branches of REMS program according to intensity of patient's health conditions which addressed by the physician. first crucial point need to check is recall medication like class 1 which include adulteration and misbranding. some medicines are control ...

6. Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View - AOL

   www.aol.com/news/amgens-osteoporosis-drug...

   The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.

7. GLP-1s: 'We're investing behind this in a big way,' says ...

   www.aol.com/finance/glp-1s-were-investing-behind...

   But with the pharma industry in the crosshairs for pricing, Amgen is keeping a focus on increased volumes of its products. "In 2018, this industry turned from price increases for 35 years or so to ...